Accelerating a Cancer Cure

The National Foundation for Cancer Research (NFCR), AIM-HI, and GoMo Health are collaborating to make it easier for people worldwide to discover and qualify for clinical trials that could be very helpful to them or a loved one that has cancer.

In order to help reduce the stress and anxiety of the unknown while participating in these clinical trials, patients will be individually nurtured through each step of the study with messages and support to help manage expectations regarding what to expect, what’s required of them, recommendations for success, and tools for empowerment to self-manage physical and psychological impact and improve outlook.

AIM-Hi Logo

Watch this 90-second video of GoMo Health CEO Bob Gold as he explains more about the Research for A Cure Clinical Trial Patient HUB

About NFCR and AIM-HI

The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization dedicated to providing scientists in the lab the funding they need to make game-changing discoveries in cancer treatments, detection and, ultimately, a cure for all types of cancer. It has distinguished itself by emphasizing long-term, transformative research often overlooked by other major funding sources and/or deemed too risky.

The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs that can potentially save cancer patients’ lives.

Are you a…

Contact us to learn how you can:

Potential Trial Participant
interested in becoming active in clinical trials?

  •  Find appropriate trials with easier access in GoMo Health aggregated format

  • Match to a clinical trial with a simplified qualification process and matching service

  • Prescreening based on population inclusion/exclusion criteria

trying to accelerate trial progress and/or increase participant awareness, recruitment and retention?

  • Reduce time and cost to acquire and retain qualified subjects and capture valuable data
  • Attract more investigator site participation
  • Support international clinical trials, awareness and participation management

Provider or Potential Investigator
interested in participating in a clinical trial?

  • Connect pre-qualified potential participants directly with your trial site to reduce staff time and cost to identify and collect necessary data
  • Increase “shows” to mandatory in-person and televideo appointments

  • Easily manage patient phone calls, identify potential adverse events, and gather information to increase adherence to therapy and regimen by incorporating a virtual care coordinator into your patient communication

Learn more about upcoming clinical trials

To learn more about participating in upcoming clinical trials, please fill out the form. Upon receipt of your information, someone will contact you regarding opportunities for participation.

Clinical Trial Research NFCR

Get in touch

  • By submitting your email, you agree to receive communications regarding opportunities related to clinical trial research and advancements.

Clinical Trial Awareness and Recruitment

Our Current Projects

Apollomics Logo


The goal of the SPARTA study is to learn if an investigational drug, called APL-101, can help patients with non-small cell lung cancer (NSCLC) or other advanced solid tumors with a genetic alteration in c-Met oncogene (such as amplification, fusion, or EXON 14 skipping mutation). Other advanced solid tumors include, but are not limited to, brain, head and neck, gastric, esophageal, biliary, pancreatic, or colorectal cancer.

Learn More

YIV-906 Study

Yiviva is launching a research study to investigate whether adding YIV-906 (the study drug), comprised of four naturally derived ingredients (licorice, skullcap, peony, and dates) to sorafenib (a currently available, typical treatment for liver cancer) can increase the length of time patients with hepatocellular carcinoma (HCC) live with their disease before it worsens. The evidence-based study drug is developed from an 1800-year-old Chinese formula.

Learn More

Donate Today and Support Research for Cancer

Everyday, our scientists make progress on the fight against cancer – but we still have a long way to go on the road to a cure, and every donation helps. Your generosity today will drive breakthroughs tomorrow!

Click Here to Donate Today